 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, the Company, we, or our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and Triclonics, today announced financial results for the second quarter that ended June 30, 2021 and provided a business update. 